These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32843454)

  • 41. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
    Sun H; Savage KJ; Karsan A; Slack GW; Gascoyne RD; Toze CL; Sehn LH; Abou Mourad Y; Barnett MJ; Broady RC; Connors JM; Forrest DL; Gerrie AS; Hogge DE; Narayanan S; Nevill TJ; Nantel SH; Power MM; Sutherland HJ; Villa D; Shepherd JD; Song KW
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):341-8. PubMed ID: 25656914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma).
    Zeng D; Desai A; Yan F; Gong T; Ye H; Ahmed M; Nomie K; Romaguera J; Champlin R; Li S; Wang M
    Am J Clin Oncol; 2019 Mar; 42(3):304-316. PubMed ID: 29419530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
    Cady FM; O'Neill BP; Law ME; Decker PA; Kurtz DM; Giannini C; Porter AB; Kurtin PJ; Johnston PB; Dogan A; Remstein ED
    J Clin Oncol; 2008 Oct; 26(29):4814-9. PubMed ID: 18645192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
    Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Whole genome sequencing demonstrates substantial pathophysiological differences of
    Bendig S; Walter W; Meggendorfer M; Bär C; Fuhrmann I; Kern W; Haferlach T; Haferlach C; Stengel A
    Leuk Lymphoma; 2021 Dec; 62(14):3420-3429. PubMed ID: 34380369
    [No Abstract]   [Full Text] [Related]  

  • 46. Management of Patients with MYC-Altered Lymphomas.
    Landsburg DJ
    Curr Hematol Malig Rep; 2016 Jun; 11(3):208-17. PubMed ID: 26983958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
    Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
    Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.
    Krull JE; Wenzl K; Hartert KT; Manske MK; Sarangi V; Maurer MJ; Larson MC; Nowakowski GS; Ansell SM; McPhail E; Habermann TM; Link BK; King RL; Cerhan JR; Novak AJ
    Blood Cancer J; 2020 Nov; 10(11):117. PubMed ID: 33168821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted next generation sequencing reveals high mutation frequency of
    Evrard SM; Péricart S; Grand D; Amara N; Escudié F; Gilhodes J; Bories P; Traverse-Glehen A; Dubois R; Brousset P; Parrens M; Laurent C
    Haematologica; 2019 Apr; 104(4):e154-e157. PubMed ID: 30309852
    [No Abstract]   [Full Text] [Related]  

  • 51. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
    Sermer D; Bobillo S; Dogan A; Zhang Y; Seshan V; Lavery JA; Batlevi C; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Palomba ML; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A
    Blood Adv; 2020 Jul; 4(14):3382-3390. PubMed ID: 32722781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Significance of
    Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
    J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms.
    Muramatsu M; Akasaka T; Kadowaki N; Ohno H; Fukuhara S; Okuma M
    Leukemia; 1997 Apr; 11 Suppl 3():318-20. PubMed ID: 9209377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with
    Uchida A; Isobe Y; Uemura Y; Nishio Y; Sakai H; Kato M; Otsubo K; Hoshikawa M; Takagi M; Miura I
    BMC Clin Pathol; 2017; 17():21. PubMed ID: 29151814
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.
    Mitobe M; Kawamoto K; Suzuki T; Suwabe T; Shibasaki Y; Masuko M; Inoue K; Miyoshi H; Ohshima K; Sone H; Takizawa J
    J Clin Exp Hematop; 2021 Mar; 61(1):42-47. PubMed ID: 33551436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
    Dheur MS; Poirel HA; Ameye G; Tilman G; Saussoy P; Defour JP; Camboni A; Van Den Neste E; Coulie PG; van Baren N
    Leuk Lymphoma; 2019 Apr; 60(4):1043-1052. PubMed ID: 30277098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.